EMA's new EURD list: what PV teams should check before the next PSUR cycle
EMA has published its list of Union reference dates and PSUR submission frequencies. The spreadsheet's contents are not summarised in the notice, so teams must check their own products.
What happened
On 18 November 2026 the European Medicines Agency published its list of Union reference dates (the EURD list) and the frequencies for submitting periodic safety update reports. The agency describes it as a key reference for marketing authorisation holders. It is distributed as a spreadsheet file on the EMA website.
The public notice does not say which entries were added, amended or removed, and nothing in the available record identifies specific substances or changed frequencies. Any claim about what moved in this version would be speculation. The practical point is simpler: the list has been reissued, and every MAH with EU authorisations should treat that as a prompt to check its own portfolio.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- EMA publishes list of Union reference dates and PSUR submission frequencies EMA · Wed 18 Nov 2026
- FDA early alert: Tablo power cord connections may overheat, Outset Medical updates instructions FDA MedWatch · Wed 18 Nov 2026
- EU Health Security Committee urges stronger action on carbapenem-resistant bacteria as infections rise European Commission (DG SANTE) · Wed 18 Nov 2026
- AIFA starts rolling review of daraxonrasib after positive CHMP opinion in pancreatic cancer AIFA · Wed 18 Nov 2026
- Portugal's antibiotic use stays below EU average, but broad-spectrum prescribing remains a concern INFARMED · Wed 18 Nov 2026
- MHRA develops AdvanceGxP service to bring GxP advice into early innovation MHRA · Wed 18 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.